WilmerHale Represents Verve Therapeutics in $94M Series B Financing

WilmerHale Represents Verve Therapeutics in $94M Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On January 19, 2021, Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, announced the successful completion of a $94 million Series B financing, led by Wellington Management Company and co-led by Casdin Capital, existing investors. New investors in the funding included Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Novo Holdings A/S, Logos Capital, Surveyor Capital (a Citadel company), RA Capital Management, and a US-based, healthcare-focused fund, alongside additional existing investors GV and Biomatics.

Proceeds from the financing will be used to advance the company’s pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership.

The WilmerHale team representing Verve includes Lia Der Marderosian, Timothy Kulis and Meghan Muncey.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel